The beginning of the end for serogroup B meningococcus?

The beginning of the end for serogroup B meningococcus?

Pokaži ostale verzije (1)

Bibliografski detalji
Glavni autori:	Snape, MD, Pollard, A
Format:	Journal article
Jezik:	English
Izdano:	2013

Slični predmeti

The beginning of the end for serogroup B meningococcus?
od: Snape, MD, i dr.
Izdano: (2013)

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.
od: McQuaid, F, i dr.
Izdano: (2015)

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.
od: Pizza, M, i dr.
Izdano: (2000)

The last of the meningococcus?
od: Segal, S, i dr.
Izdano: (2004)

The price of prevention: what now for immunisation against meningococcus B?
od: Moxon, R, i dr.
Izdano: (2013)

The meningococcus tamed?
od: Pollard, A, i dr.
Izdano: (2002)

The Course of Generalized Meningococcal Infection Caused by Meningococcus Serogroup W135
od: M. V. Ivanova, i dr.
Izdano: (2016-11-01)

Keeping the meningococcus out of the media.
od: Pollard, A, i dr.
Izdano: (1997)

Where next? The emergence of hypervirulent W meningococcus in the Netherlands
od: Snape, M, i dr.
Izdano: (2017)

No conspiracy regarding recommendation for a group B meningococcus vaccine.
od: Pollard, A, i dr.
Izdano: (2014)

The Establishment and Diversification of Epidemic-Associated Serogroup W Meningococcus in the African Meningitis Belt, 1994 to 2012
od: Adam C. Retchless, i dr.
Izdano: (2016-12-01)

Meningococcus serogroup C clonal complex ST-10217 outbreak in Zamfara State, Northern Nigeria
od: Brenda A. Kwambana-Adams, i dr.
Izdano: (2018-09-01)

Policies for the immunization against serogroup B meningococcus for adolescents immunized during the first two years of life: A mini review
od: Claudia Palmieri, i dr.
Izdano: (2024-12-01)

Meningococcus, this famous unknown
od: dos Santos Souza, Isabel, i dr.
Izdano: (2021-07-01)

Will booster doses be required for serogroup B meningococcal vaccine?
od: McQuaid, F, i dr.
Izdano: (2014)

No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales - Authors' reply
od: Snape, MD, i dr.
Izdano: (2006)

The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology
od: Vega Masignani, i dr.
Izdano: (2019-04-01)

Safety and tolerability of Meningococcus B vaccine in patients with chronical medical conditions (CMC)
od: L. Nicolosi, i dr.
Izdano: (2019-10-01)

Serogroup B meningococcal vaccines-an unfinished story.
od: Sadarangani, M, i dr.
Izdano: (2010)

A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.
od: Su, E, i dr.
Izdano: (2011)

Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
od: Pollard, A, i dr.
Izdano: (2013)

Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine.
od: Snape, MD, i dr.
Izdano: (2009)

Towards an improved serogroup B Neisseria meningitidis vaccine.
od: Perrett, K, i dr.
Izdano: (2005)

Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus
od: Sheerin, D, i dr.
Izdano: (2022)

Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus
od: Dylan Sheerin, i dr.
Izdano: (2022-06-01)

A vaccine against serogroup B Neisseria meningitidis: Dealing with uncertainty
od: Andrews, S, i dr.
Izdano: (2014)

A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty.
od: Andrews, S, i dr.
Izdano: (2014)

Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes
od: M. Giuliani, i dr.
Izdano: (2018-02-01)

A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
od: Martin, N, i dr.
Izdano: (2013)

Challenges and progress in the development of a serogroup B meningococcal vaccine.
od: Lewis, S, i dr.
Izdano: (2009)

MENINGOCOCCUS GROWTH STIMULATORS FOR MENINGITIS DIAGNOSTICS BASED ON 2-HYDROXYLALKYLAMINE SALTS
od: A. N. Mirskova, i dr.
Izdano: (2012-09-01)

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination
od: De Whalley, P, i dr.
Izdano: (2013)

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
od: de Whalley, P, i dr.
Izdano: (2013)

Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
od: Snape, MD, i dr.
Izdano: (2010)

Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine
od: O'Connor, D, i dr.
Izdano: (2014)

An OMV vaccine derived from a capsular group B meningococcus with constitutive FetA expression: preclinical evaluation of immunogenicity and toxicity
od: Norheim, G, i dr.
Izdano: (2015)

TMS--the beginning of the end or the end of the beginning?
od: Ebmeier, K, i dr.
Izdano: (2008)

Production of low-avidity antibody by infants after infection with serogroup B meningococci.
od: Pollard, A, i dr.
Izdano: (2000)

Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.
od: Kelly, D, i dr.
Izdano: (2009)

Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.
od: Khatami, A, i dr.
Izdano: (2011)